These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20850365)

  • 41. Differential effects of primary hyperparathyroidism on ultrasound properties of bone.
    Ingle BM; Thomas WE; Eastell R
    Osteoporos Int; 2002 Jul; 13(7):572-8. PubMed ID: 12111018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study.
    Glüer CC; Eastell R; Reid DM; Felsenberg D; Roux C; Barkmann R; Timm W; Blenk T; Armbrecht G; Stewart A; Clowes J; Thomasius FE; Kolta S
    J Bone Miner Res; 2004 May; 19(5):782-93. PubMed ID: 15068502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.
    Johnell O; Kanis JA; Black DM; Balogh A; Poor G; Sarkar S; Zhou C; Pavo I
    J Bone Miner Res; 2004 May; 19(5):764-72. PubMed ID: 15068500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adherence to raloxifene therapy: assessment methods and relationship with efficacy.
    Finigan J; Naylor K; Paggiosi MA; Peel NF; Eastell R
    Osteoporos Int; 2013 Nov; 24(11):2879-86. PubMed ID: 23695420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women.
    Ziller M; Herwig J; Ziller V; Kauka A; Kostev K; Hadji P
    Gynecol Endocrinol; 2012 Dec; 28(12):1002-5. PubMed ID: 22835159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leisure physical activity is associated with quantitative ultrasound measurements independently of bone mineral density in postmenopausal women.
    Blanchet C; Giguère Y; Prud'homme D; Turcot-Lemay L; Dumont M; Leduc G; Côte S; Laflamme N; Rousseau F; Dodin S
    Calcif Tissue Int; 2003 Oct; 73(4):339-49. PubMed ID: 12874703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.
    Rehman Q; Lang T; Modin G; Lane NE
    Arthritis Rheum; 2002 May; 46(5):1292-7. PubMed ID: 12115236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
    Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
    Eriguchi R; Umakoshi J; Miura S; Sato Y
    Clin Nephrol; 2009 Dec; 72(6):423-9. PubMed ID: 19954718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of fracture discrimination using calcaneal quantitative ultrasound and dual X-ray absorptiometry in women with a history of fracture at sites other than the spine and hip.
    Frost ML; Blake GM; Fogelman I
    Calcif Tissue Int; 2002 Sep; 71(3):207-11. PubMed ID: 12154392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
    Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultrasound transmission speed and ultrasound bone profile score (UBPS) of the phalanges in normal women and women with osteoporosis.
    Soballa T; Wüster C; Schlegel J; Cadossi R; Isani R; Battista S; Heilmann P; Ziegler R
    Horm Metab Res; 1998 Aug; 30(8):536-41. PubMed ID: 9761387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hand ultrasound for osteoporosis screening in postmenopausal women.
    Benitez CL; Schneider DL; Barrett-Connor E; Sartoris DJ
    Osteoporos Int; 2000; 11(3):203-10. PubMed ID: 10824235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of serial bone mineral density testing for osteoporosis.
    Crandall C
    J Womens Health Gend Based Med; 2001 Nov; 10(9):887-95. PubMed ID: 11747684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative ultrasound and bone densitometry to evaluate the risk of nonspine fractures: a prospective study.
    Gnudi S; Ripamonti C; Malavolta N
    Osteoporos Int; 2000; 11(6):518-23. PubMed ID: 10982168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ultrasound measurements at the proximal phalanges in healthy women and patients with hip fractures.
    Alenfeld FE; Wüster C; Funck C; Pereira-Lima JF; Fritz T; Meeder PJ; Ziegler R
    Osteoporos Int; 1998; 8(5):393-8. PubMed ID: 9850344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.